NCT06269692 (SMART-DEF) is a NA clinical trial of MRI screening in Myocardial Infarction, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT06269692?

NCT06269692 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT06269692?

Interventions in NCT06269692: MRI screening, Implantable Loop Recorder, Implantable Cardioverter Defibrillator.

What condition does NCT06269692 study?

NCT06269692 studies Myocardial Infarction, Ventricular Tachycardia, Ventricular Fibrillation, Sudden Cardiac Death.

Is NCT06269692 still recruiting?

NCT06269692 is currently not yet recruiting. Last updated 21 February 2024.

Last reviewed 2024-02-21 · How we verify

NCT06269692: SMART-DEF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MAgnetic Resonance Imaging-guided implanTation of Cardioverter DEFibrillators

Not yet recruiting NA Last updated 21 February 2024

What this trial tests

NA trial testing MRI screening in Myocardial Infarction in 1,812 participants. Not yet recruiting.

Timeline

1 April 2024

Primary endpoint
1 April 2030

1 April 2030

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	1,812
Start date	1 April 2024
Primary completion	1 April 2030
Estimated completion	1 April 2030
Sites	1 location across France

Drugs / interventions tested

MRI screening
Implantable Loop Recorder
Implantable Cardioverter Defibrillator

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →
Ventricular Tachycardia — all drugs for Ventricular Tachycardia →
Ventricular Fibrillation — all drugs for Ventricular Fibrillation →
Sudden Cardiac Death — all drugs for Sudden Cardiac Death →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Myocardial Infarction or Ventricular Tachycardia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Implantable cardioverter-defibrillators (ICD) are currently recommended for the primary prevention of sudden cardiac death (SCD) in patients with a remote (\>6 weeks) myocardial infarction (MI) and a low (≤35%) left ventricular ejection fraction (LVEF). Ventricular tachycardia (VT) and/or ventricular fibrillation (VF), which are responsible for most SCDs, result from the presence of surviving myocytes embedded within fibrotic MI-scar. The presence of these surviving myocytes, as well as their specific arrhythmic characteristics, is not captured by LVEF. Hence, the use of LVEF as a unique risk-stratifier of SCD results in a low proportion (17 to 31%) of appropriate ICD device therapy at 2 years. Consequently, most patients with a prophylactic ICD do not present VT/VF requiring ICD therapy prior to their first-ICD battery depletion. Thus, many patients are exposed to ICD complications, such as inappropriate shocks, without deriving any health benefit. Therefore, the current implantation strategy of prophylactic ICDs, based on LVEF only, needs to be improved in post-MI patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI screening

Trials testing the same drug.

NCT02324894 — Initial Evaluation of Ultra FAST Breast Magnetic Resonance in Breast Cancer Screening: Comparative Study With Mammograph · NA · withdrawn

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06269692 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 21 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06269692.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing